Under the terms of the deal, Lonza will support Bioqube Ventures during the due diligence of candidate biotechs and provide a tailored offering of advice and services to its portfolio companies. It will offer its expertise and technology on molecules ranging from monoclonal antibodies, complex proteins and small molecules to antibody-drug conjugates.

“This framework agreement provides Bioqube Ventures and its portfolio companies with a range of services for its late discovery and early development needs. Our customized and scalable solutions demonstrate our commitment to enabling emerging biotechs to take their drug candidates to the clinic,” said Pnina Weitz, global head of venture capital business development & relationship management at Lonza.

The partners said the holistic approach to drug substance and drug product development and manufacturing across various platforms significantly simplifies the supply chain, reduces process complexity and allows for shortened development timelines.

Author: Elaine Burridge, Freelance Journalist